Medicus Pharma’s (MDCX) Buy Rating Reiterated at D. Boral Capital

Medicus Pharma (NASDAQ:MDCX)‘s stock had its “buy” rating reissued by analysts at D. Boral Capital in a research note issued to investors on Monday,Benzinga reports. They presently have a $27.00 price objective on the stock.

MDCX has been the topic of a number of other reports. Zacks Research upgraded Medicus Pharma to a “hold” rating in a research report on Monday, September 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Medicus Pharma in a research note on Monday, December 8th. Two analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $23.50.

Medicus Pharma Stock Down 3.1%

MDCX stock opened at $1.89 on Monday. Medicus Pharma has a twelve month low of $1.68 and a twelve month high of $8.94. The company has a market cap of $41.64 million and a PE ratio of -0.88. The business’s 50-day simple moving average is $2.25 and its 200 day simple moving average is $2.45.

Medicus Pharma (NASDAQ:MDCX) last released its quarterly earnings data on Friday, November 14th. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.27). On average, equities research analysts anticipate that Medicus Pharma will post -1.14 EPS for the current year.

Institutional Trading of Medicus Pharma

Large investors have recently bought and sold shares of the business. Jane Street Group LLC acquired a new position in shares of Medicus Pharma during the second quarter worth about $41,000. Osaic Holdings Inc. lifted its position in shares of Medicus Pharma by 180.0% in the second quarter. Osaic Holdings Inc. now owns 14,000 shares of the company’s stock worth $42,000 after purchasing an additional 9,000 shares in the last quarter. Brave Asset Management Inc. bought a new position in Medicus Pharma in the third quarter valued at $46,000. Wilmington Savings Fund Society FSB bought a new position in Medicus Pharma in the third quarter valued at $59,000. Finally, May Hill Capital LLC acquired a new stake in Medicus Pharma in the 2nd quarter valued at $107,000.

About Medicus Pharma

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.